 |
“合作创新 驱动增长” |
|
| |
...... |
|
|
| |
BMS ups investment in China |
|
| |
1.Emphasis will be placed on innovative medicine and drugs tailored to the local market, as BMS has become a strong driver of the biopharmaceutical company's progress in China.
2. In late 2009, Baraclude, BMS' self-developed anti-viral treatment for hepatitis B, was included in China's updated National Reimbursement Drug List. So far, it has been included in the local reimbursement drug list of more than 20 provinces.
3. BMS ranked 131st in the Fortune Global 500 in 2010 and sixth in the pharmaceutical industry on the list, while its Chinese business currently contributes 2 percent of its global achievements, indicating huge growth potential. That has led to a series of the leading global pharmaceutical companies competing to introduce their drugs to China or enhance their R&D capabilities with partners....... |
|
|
| |
医学论坛报：专注于未被满足的医学需求 |
|
| |
Since the successful transformation into a BioPharma leader several years ago, BMS has focused its strategy on “unmet medical needs” and responded to new challenges through its BioPharma strategy. Recently, the journalist has learnt more about the BioPharma concept through explorations of BMS’ endeavors in R&D and quality control....... |
|
|
| |
新华网：百时美施贵宝中国区换帅 向生物制药企业转型 |
|
| |
Dr. Jean-Christophe Pointeau is appointed as the new China president of BMS China/SASS and his working experience in BMS.As a core market for BMS global development, BMS China has made special strategy and plan for China future growth...... |
|
|
| |
新闻晚报：关注丙肝经济负担研究 |
|
| |
BMS Foundation donates 246,932 USD to Wujieping Medical Foundation to study Hepatitis C burden. The program intends to cover 16 provinces, 35 hospitals and 1050 hepatitis C patients....... |
|
|
| |
新闻晨报：“强效抗病毒”应贯穿慢乙肝治疗始末 |
|
| |
When patients receiving anti-viral treatment, it is critical that the viral load must be controlled to the lowest possible, be the patient is treatment-naïve, or treatment-experienced, be the patient HBeAg-positive or HBeAg-negative, be the patient in compensated or de-compensated stage....... |
|
|
| |
三联生活周刊：子弹、银行家和世界肝炎日 |
|
| |
While Asia and Africa are primarily plagued by hepatitis B, in Europe and North America, Hepatitis C is at the center stage. Though no vaccine as yet available, 40% of the Hepatitis C patients can be cured....... |
|
|
| |
新闻晚报：最大规模乙肝抗病毒药物临床实践数据发布 全程强效抑制病毒是根本 |
|
| |
When patients receiving anti-viral treatment, it is critical that the viral load must be controlled to the lowest possible, be the patient is treatment-naïve, or treatment-experienced, be the patient HBeAg-positive or HBeAg-negative, be the patient in compensated or de-compensated stage....... |
|
|
| |
经济杂志：小学生肝炎防治教育新模式的创建者 |
|
| |
“Delivering Hope” Primary School Student Hepatitis Education Program is the first hepatitis prevention health project which combine education system......... |
|
|
| |
医药经理人杂志：肝病防治“马拉松”式慈善 |
|
| |
The Bristol-Myers Squibb (BMS) Foundation’s Delivering...... |
|
|
|
